Engagement & Persistence

Program persistence, engagement frequency, discontinuation reasons, and follow-up performance.

Privacy: no group under 11 shownSample data

6-month persistence

79%

remain on treatment

Observed

Meaningful actions / week

2.8

per active member

Observed

Timely follow-up

80%

258 of 323 cases

Observed

Active members

1,326

currently engaged

Observed

Program persistence

Cohort

PayRX cohort retention vs. an illustrative industry benchmark. At 12 months, 1,158 members remain active.

Engagement frequency

1,326 active members

Daily check-ins955 (72%)

Weekly check-ins239 (18%)

Monthly or less133 (10%)

Avg check-ins / week

3.2

Observed

Message response rate

84%

Observed

Refill adherence

91%

Observed

Discontinuation reasons

Side effects

20 (31.3%)

Cost / coverage

14 (21.9%)

Refill difficulties

10 (15.6%)

Clinical decision

8 (12.5%)

Other / unknown

12 (18.8%)

Total discontinued64 (100%)

Among 64 members who discontinued within 12 months. Each member has one primary reason.

Timely follow-up

80%

258 of 323 cases requiring follow-up received a same-day response.

Employee Privacy Protected by Design

Employer reporting is designed to present aggregate workforce and health-program insights without exposing individual clinical records. Small-group reporting restrictions help reduce the risk of employee identification.

Sample dataPrivacy-restricted reporting

Aggregated information is not described as HIPAA-de-identified unless applicable de-identification requirements have been satisfied and verified.